Merck scores first US PD-1 approval

Share this article:
Merck scores first US PD-1 approval
Merck scores first US PD-1 approval

Merck is first to cross the US regulatory finish line for PD-1 inhibitors. The FDA approved the drug previously known as pembrolizumab, now known as Keytruda, for patients with unresectable or metastatic melanoma who have already taken Bristol-Myers Squibb's Yervoy (ipilimumab).

The FDA says melanoma accounts for around 5% of all new cancers diagnosed in the US. Merck's new drug is the sixth new melanoma treatment the regulator has approved since 2011, but this approval is a breakout for a drug class that has become a magnet for industry watchers. Multiple manufacturers are banking on immuno-oncology treatments, including AstraZeneca, Bristol-Myers and Roche.

The Street's Adam Feuerstein tweeted that a Merck spokesperson priced the new drug at $12,500 a month. A typical treatment will last 6.2 months.

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...